Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.
News & Analysis: Biogen
Investors cheer as Biogen wins a patent ruling involving its blockbuster multiple sclerosis drug.
A favorable patent ruling could translate to smoother sailing for Biogen's top-selling drug.
Biogen's decision to forgo a major deal weighed on its shares in 2019.
The decision to reanimate an Alzheimer's disease program that died eight months earlier gave investors a lot to think about.
Biogen's shares are getting a boost from a pair of catalysts this morning.
Biogen's swing and miss in Alzheimer's disease has weighed on its shares this year.
The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.
The clinical-stage gene therapy company got some love from biotech giant Biogen last month.
Biogen's closely-watched Alzheimer's drug fails to move in the needle in two late-stage trials.
Biogen takes out Nightstar Therapeutics for its pipeline of novel gene therapies.